Business Wire

ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial

Share

ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.

ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.

Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, Soliris and Ultomiris, patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.

ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.

“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”

About ImmunAbs Inc.

ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

HyunJung Jung
Business Development Manager
Hyunjung.Jung@ImmunAbs.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global Alliance on Green Economy launched during World Green Economy Summit in Dubai3.10.2022 09:00:00 CEST | Press release

Under the patronage of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the 8th World Green Economy Summit (WGES) concluded in Dubai. It was organised by the World Green Economy Organization (WGEO), Dubai Electricity and Water Authority (DEWA), and the Dubai Supreme Council of Energy. The summit was held under the theme ‘Climate Action Leadership through Collaboration: The Roadmap to Net-Zero’. A large number of ministers, experts, decision-makers, officials, representatives of institutions, and the academic community from around the world took part in the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005176/en/ Global Alliance on Green Economy launched during World Green Economy Summit in Dubai (Photo: AETOSWire) During a ministerial roundtable on green economy at WGES with around 25 ministers and officials from around the world, HE Saeed Mohammed Al T

Slate Asset Management Holds Third Close of Slate European Essential Real Estate Income Fund3.10.2022 09:00:00 CEST | Press release

Slate Asset Management ("Slate"), a global alternative investment platform targeting real assets, today announced that Slate European Essential Real Estate Income Fund (“SEEREIF” or the “Fund”) has reached its third close of the 2022 calendar year, significantly increasing the Fund’s available equity commitments for deployment. SEEREIF is backed by a diversified group of global institutional investors. The Fund is part of Slate’s core-plus investment strategy focused on European essential real estate, which targets cash yielding assets critical to the supply chain with high credit quality tenants, such as grocery and other essential consumer goods providers, healthcare assets, and affiliated warehouses and logistics centers. Jerry Cain, Managing Director of Investor Relations at Slate, said: “For the second quarter in a row, SEEREIF has closed on capital commitments from Slate’s global institutional partners, indicating that our investors recognize the uniquely resilient nature of this

Monument Re Announces Merger of AME Life Lux S.A. Into Monument Assurance Luxembourg S.A.3.10.2022 09:00:00 CEST | Press release

Monument Re announced today that AME Life Lux S.A. will merge into Monument Assurance Luxembourg S.A. following receipt of regulatory approval from the Commissariat aux Assurances. As a result, Monument Assurance Luxembourg S.A. will be the sole Monument Luxembourg entity following the merger. Monument Re Limited is a reinsurer and asset consolidator with a proven track record in the acquisition and operation of portfolios or direct insurers in Europe. Monument Re has a presence in Bermuda which has full Solvency II equivalence along with Switzerland. The Monument Re Group also operates through its subsidiaries in Belgium, Ireland, Isle of Man, Guernsey and Luxembourg, with branches in Spain, Italy and Germany. Each entity is subject to local regulation and Monument Re is subject to Group Supervision by the Bermuda Monetary Authority. Monument Assurance Luxembourg S.A. is a fully licensed Luxembourg life insurance company regulated by the Commissariat aux Assurances, with branches in S

Prodapt Launches OpenFibreXchange to Accelerate Pan-UK Digital Connectivity3.10.2022 08:00:00 CEST | Press release

Prodapt, a leading global consulting, technology, and managed services provider to the connectedness industry, today announced the launch of its OpenFibreXchange (OFX) that will enable Internet Service Providers (ISPs) to rapidly connect with the regional fibre operators to boost high-speed digital connectivity across the UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005312/en/ With a singular focus on the Connectedness industry, Prodapt’s OpenFibreXchange, built on cloud-native, open-source technology, will enable wholesale fibre aggregation in the UK to accelerate digital Connectedness. ISPs can seamlessly connect with regional fibre operators via OFX to deliver pan-UK digital connectivity. Prodapt is committed to accelerating the digitisation of Britain and connecting hard-to-reach communities. The investment in OFX resulted from open discussions with delegates from retail & wholesale fibre AltNets, incumbent o

Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by GN Corporation3.10.2022 08:00:00 CEST | Press release

Treatment of cancer using one’s own immune cells, natural killer (NK) cells and T-cells, called autologous immune enhancement cell therapy (AIET) administered along with conventional chemotherapy, radiotherapy and surgery, practiced in Japan for long is now offered in Vinmec hospital, Hanoi, Vietnam, following technology transfer by GN Corporation. Cancer patients from neighboring countries are now visiting Vinmec hospital for this treatment. Autologous immune-cell therapy, regulated by the regenerative medicine law in Japan, uses lab-expanded autologous immune cells, without animal proteins or genetic manipulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221002005087/en/ NK cells and T-cells in vitro culture method, without feeder cells or animal serum or genetic manipulation, for immune-cell therapy to cancer patients developed and practiced in Japan was tech-transferred to Vinmec Hospital, Hanoi, Vietnam, which was